 |
Neuronetics
Last updated: February 25, 2024
David Brock, Medical Director & Christopher Thatcher, President & CEO
Country: USA | Funding: $373.4M (+)
Website: http://www.neuronetics.com/
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
Website: http://www.neuronetics.com/
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
